NEWARK, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, ...
Thursday, CymaBay Therapeutics Inc (NASDAQ:CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due ...
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback